China will begin easing an export ban on automotive computer chips vital to production of cars across the world as part of a trade deal struck between the US and China, the White House has said.

The White House confirmed details of the deal in a new fact sheet after Xi Jinping and Donald Trump met in South Korea this week.

The nations also reached agreements on US soybean exports, the supply of rare earth minerals, and the materials used in production of the drug fentanyl.

The deal de-escalates a trade war between the world’s two largest economies after Trump hit China with tariffs after he entered office this year, leading to rounds of retaliatory tariffs and global business uncertainty.

Chinese Embassy in Washington spokesman Liu Pengyu told the BBC in a statement that details of the agreements reached had been shared by “competent authorities”.

“China-US economic and trade relations are mutually beneficial in nature,” he said.

“As President Xi Jinping noted, the business relationship should continue to serve as the anchor and driving force for China-US relations, not a stumbling block or a point of friction.”

Speaking on Sunday following the release of the deal details, Treasury Secretary Scott Bessent told CNN: “We don’t want to decouple from China… (But) they’ve shown themselves to be an unreliable partner.”

Much of what is in Saturday’s fact sheet was announced by Trump and other officials following the meeting between the two leaders.

Trump had described the talks, held in South Korea, as “amazing”, while Beijing had said they had reached a consensus to resolve “major trade issues”.

One of the issues addressed in the deal was the export of automotive computer chips. There had been concern that a lack of chips from Nexperia, which has production facilities in China, could create global supply chain issues.

Nexperia is a Chinese-owned company, but is based in the Netherlands. About 70% of Nexperia chips made in Europe are sent to China to be completed and re-exported to other countries.

The fact sheet states that China will “take appropriate measures to ensure the resumption of trade from Nexperia’s facilities in China, allowing production of critical legacy chips to flow to the rest of the world”.

It follows Beijing saying on Saturday that it was considering exempting some firms from the ban.

Last month, the likes of Volvo Cars and Volkswagen warned a chip shortage could lead to temporary shutdowns at their plants, and Jaguar Land Rover said the lack of chips posed a threat to their business.

On other key issues, Beijing will now pause export controls it brought in last month on rare earth minerals – vital in the production of cars, planes and weapons – for a year.

The White House also said it would lower tariffs brought in to curb the import of fentanyl into the US, with China agreeing to take “significant measures” to deal with the issue.

Fentanyl is a synthetic drug manufactured from a combination of chemicals, and while it is approved for medical use in the US, the powerful and highly-addictive substance has since become the main drug responsible for opioid overdose deaths in the US.

The chemicals used in its manufacturing, some of which have legitimate uses, are mostly sourced from China.

On soybeans, China has committed to buying 12 million tonnes of US soybeans in the last two months of 2025, and 25 million metric tonnes in each of the following three years – which is roughly the level they were previously at.

China’s decision to stop purchasing soybeans from the US earlier this year denied American farmers access to their largest export market.

In response, Trump revived a bailout for farmers which was in place during his first term in office.

The National Company Law Appellate Tribunal (NCLAT) has ruled that the Competition Commission of India (CCI) does not have the power to investigate disputes related to patented products, holding that the Patent Act takes precedence over the Competition Act in such cases, PTI reported.Dismissing an appeal against a CCI order that had closed a complaint against Swiss pharma major Vifor International (AG), a two-member NCLAT bench said that the fair trade regulator lacks jurisdiction to examine such matters, PTI reported.“Considering the judgment of the Delhi High Court in the case of Telefonaktiebolaget LM Ericsson (PUBL) and the Supreme Court in SLP No. 25026/2023, it is apparent that the CCI lacks the power to examine the allegations made against Vifor International (AG),” the tribunal observed.Vifor International held the patent for Ferric Carboxymaltose (FCM) injection, a drug used to treat Iron Deficiency Anaemia (IDA). The tribunal stated: “The Patent Act will prevail over the Competition Act in the facts of this case, as the subject matter of contention is FCM, which was developed and patented by Respondent No. 2 (Vifor International).”NCLAT noted that Section 3(5) of the Competition Act provides specific protection to patent holders to restrain infringement or impose reasonable conditions to safeguard their rights. “The Competition Act, in Section 3(5), has laid down that the Act will not restrict the right of any person in protecting his rights under the Patent Act,” it said.The appeal was filed by Swapan Dey, CEO of a hospital offering free dialysis services under the Pradhan Mantri National Dialysis Programme (PMNDP). Dey alleged that Vifor’s “anti-competitive and abusive conduct” had made FCM injections unaffordable and inaccessible to patients.However, the CCI had closed the case in its October 25, 2022 order, finding no prima facie contravention under Sections 3(4) or 4 of the Competition Act. Dey then challenged the order before NCLAT, arguing that the CCI failed to properly define the relevant market or assess Vifor’s dominance.Vifor countered the claim, asserting that the CCI lacked jurisdiction since the matter involved a patented molecule governed by the Patent Act. The company also informed the tribunal that its patent for FCM, granted on June 25, 2008, had expired on October 21, 2023, making it freely available for manufacturing and sale.NCLAT held that while the patent’s expiry meant the drug had entered the public domain, the key question was jurisdiction—whether CCI could have examined the issue when the product was still under patent protection.Citing the Delhi High Court’s earlier decision in Telefonaktiebolaget LM Ericsson (PUBL), which held that the Patent Act overrides the Competition Act, the tribunal noted that the Supreme Court had upheld that position by dismissing CCI’s appeal on September 2, 2025.“Following the judicial guidance as noted above, we hold that there is no merit in this appeal. Accordingly, the appeal is dismissed,” NCLAT concluded.